Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To test the effect of pramlintide on body weight in clozapine- and olanzapine-induced weight
gain in persons with schizophrenia who are currently taking either drug; measures of the
metabolic syndrome will be evaluated as well.